You are currently viewing a new version of our website. To view the old version click .
  • Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
  • Guidelines
  • Open Access

13 April 2007

Small-Cell Lung Cancer Diagnostic and Therapeutic Recommendations of Polish Lung Cancer Group

,
,
,
,
,
,
,
,
and
1
Klinika Nowotworów Płuca i Klatki Piersiowej, Centrum Onkologii—Instytut im. M. Skłodowskiej-Curie, ul. Rentgena 5, 02-781 Warszawa, Poland
2
Instytut Chorób Płuc i Gruźlicy w Warszawie, 02-781 Warszawa, Poland
3
Centrum Onkologii-Instytut w Krakowie, Krakowie, Poland
4
Wielkopolskie Centrum Chorób Płuc i Gruźlicy w Poznaniu, Poznaniu, Poland

Abstract

Small-cell lung cancer is characterized by an aggressive clinical course with high tendency for early dissemination. At presentation, patients are usually symptomatic and with hilar or mediastinal mass at radiography. Staging should be focused on identifying any evidence of distant spread. Chemotherapy including cisplatin and etoposide is a cornerstone of treatment for all patients. Limited-stage disease should be managed by chemotherapy combined with concurrent chest irradiation. All patients who achieve complete response should be considered for elective cranial irradiation. Surgical treatment may be used in highly selected patients with TNM stage I disease, and surgery should always be combined with chemotherapy. Extensive-stage disease should be managed by multi-agent chemotherapy alone. Long-term survivorus should undergo careful monitoring for development of a second primary tumour.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.